1. Griffith DE, Philley JV, Wallace RJ, Antimycobacterial agents. In: Bennett JE, Dolin R, Blaser MJ (eds). In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 9th
ed. Elsevier, Philadelphia 2020:477-496
2. Sonika U, Kar P. Tuberculosis and liver disease: management issues. Trop Gastroenterol. 2012; 33(2):102-6.
3. Official American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuber-
culosis. CID 2016:63, 854-867
4. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
5. Tüberküloz Tanı ve Tedavi Rehberi, Sağlık Bakanlığı Yayın No, Ankara, 2019
6. Carr W, Kurbatova E, Starks A, et al. Interim Guidance: 4-Month Rifapentine- Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis – United States, 2022.
MMWR Morb Mortal Wkly Rep 2022; 71:285.
7. Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant TuberculosisAn Official ATS/CDC/ERS/IDSA Clinical Practice Guideline, Am J Respir Crit Care.2019: 200 (10), e93–e142
8. Guideline for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controller Association and CDC, 2020; MMWR; February 14,2020, Vol.69,
No:1
9. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J
Respir Crit Care Med. 2007;175:367-416
10. National Institutes of Health. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.https://aidsinfo.nih.gov/guidelines. Accessed May 21, 2018.
11. Sterling TR, Villarino ME, Borisov AS, et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med.
2011;365:2155–2166.
12. Ngo SC, Zimhony O, Chung WJ, et al. Inhibition of isolated Myco- bacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob Agents Chemother 2007; 51:2430-5
13. Rey-Jurado E, Tudó G, Martínez JA, González-Martín J. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis. Tuberculosis. 2012; 92(3):260-3
14. Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and
extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol. 2010;5(2):96-114
15. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med.
2006; 174:331-8
16. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med. 2008;178: 1180–1185.
17. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508–1518.
18. Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother.
2010;65:775–783.
19. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10:621-9
20. VannelliTA,DykmanA,OrtizdeMontellanoPR.The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 2002; 277: 12824-9
21. Payen MC, De Wit S, Martin C, et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16:558–560.
22. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid- containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J.
2013;41:1386–1392.
23. BensonCA,WilliamsPL,CurrierJS,etal.Aprospective,randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment
of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:1234-43
24. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. American Thoracic Society
statement. Am J Respir Crit Care Med. 2007;175:367–416